Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM

• DOI: 10.1080/14796694.2024.2368450
• Publication Date: 2024-07-29T10:53:35Z
• Authors: Lucia Masarova; Srdan Verstovsek; Tom Liu; Sumati Rao; Gautam Sajeev; Mirko Fillbrunn; Ryan Simpson; Weilong Li; Joseph Yang; Yvette Le Lorier; Boris Gorsh; James Signorovitch

Aim: To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol. Methods: Cost and time burden were calculated based on the transfusion status of patients in the MOMENTUM trial and estimates extracted from previous studies. Results: Reductions in transfusion associated with momelotinib are projected to result in cost and time savings compared with danazol in transfusion-dependent and transfusion-independent/requiring patients with myelofibrosis, respectively: annual medical costs ($53,143 and $46,455 per person), outpatient transfusion costs ($42,021 and $8,370 per person) and annual time savings (173 and 35 h per person). Conclusion: Fewer transfusions with momelotinib are projected to result in cost and time savings in patients with myelofibrosis and anemia compared with danazol.